Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 199

1.

Hemagglutinin consensus-based prophylactic approaches to overcome influenza virus diversity.

Sautto GA, Ross TM.

Vet Ital. 2019 Sep 30;55(3):195-201. doi: 10.12834/VetIt.1944.10352.1.

2.

Three- vs. Four-Year Emergency Medicine Training Programs.

Ross TM, Wolfe RE, Murano T, Alleyne P, Dyne PL, Cheaito MA, Lotfipour S, Kazzi A.

J Emerg Med. 2019 Oct 5. pii: S0736-4679(19)30625-0. doi: 10.1016/j.jemermed.2019.07.013. [Epub ahead of print]

PMID:
31594743
3.

Age-Related Pathology Associated with H1N1 A/California/07/2009 Influenza Virus Infection.

Bissel SJ, Carter CE, Wang G, Johnson SK, Lashua LP, Kelvin A, Wiley CA, Ghedin E, Ross TM.

Am J Pathol. 2019 Oct 1. pii: S0002-9440(19)30749-7. doi: 10.1016/j.ajpath.2019.08.017. [Epub ahead of print]

PMID:
31585069
4.

Preexisting influenza specific immunity and vaccine effectiveness.

Jang H, Ross TM.

Expert Rev Vaccines. 2019 Oct 11:1-9. doi: 10.1080/14760584.2019.1675519. [Epub ahead of print]

PMID:
31575308
5.

Historical H1N1 Influenza Virus Imprinting Increases Vaccine Protection by Influencing the Activity and Sustained Production of Antibodies Elicited at Vaccination in Ferrets.

Francis ME, McNeil M, Dawe NJ, Foley MK, King ML, Ross TM, Kelvin AA.

Vaccines (Basel). 2019 Sep 28;7(4). pii: E133. doi: 10.3390/vaccines7040133.

6.

2018 ISV Congress: advances in the 100 years since the world's deadliest pandemic.

Doolan DL, Ross TM.

Hum Vaccin Immunother. 2019;15(9):2006-2008. doi: 10.1080/21645515.2019.1660544. No abstract available.

7.

Structural and antigenic characterization of a computationally-optimized H5 hemagglutinin influenza vaccine.

Bar-Peled Y, Huang J, Nuñez IA, Pierce SR, Ecker JW, Ross TM, Mousa JJ.

Vaccine. 2019 Sep 24;37(41):6022-6029. doi: 10.1016/j.vaccine.2019.08.062. Epub 2019 Aug 31.

PMID:
31481254
8.

Computationally optimized broadly reactive vaccine based upon swine H1N1 influenza hemagglutinin sequences protects against both swine and human isolated viruses.

Skarlupka AL, Owino SO, Suzuki-Williams LP, Crevar CJ, Carter DM, Ross TM.

Hum Vaccin Immunother. 2019;15(9):2013-2029. doi: 10.1080/21645515.2019.1653743.

9.

Corrigendum to "A computationally designed H5 antigen shows immunological breadth of coverage and protects against drifting avian strains" [Vaccine 37 (2019) 2369-2376].

Ross TM, DiNapoli J, Giel-Moloney M, Bloom CE, Bertran K, Balzli C, Strugnell T, Oomen RP, Sá E Silva M, Mebatsion T, Bublot M, Swayne DE, Kleanthous H.

Vaccine. 2019 Sep 3;37(37):5664. doi: 10.1016/j.vaccine.2019.07.058. Epub 2019 Aug 2. No abstract available.

PMID:
31383487
10.

Impact of age and pre-existing immunity on the induction of human antibody responses against influenza B viruses.

Carlock MA, Ingram JG, Clutter EF, Cecil NC, Ramgopal M, Zimmerman RK, Warren W, Kleanthous H, Ross TM.

Hum Vaccin Immunother. 2019;15(9):2030-2043. doi: 10.1080/21645515.2019.1642056. Epub 2019 Aug 8.

11.

Vaccination with a chikungunya virus-like particle vaccine exacerbates disease in aged mice.

Arévalo MT, Huang Y, Jones CA, Ross TM.

PLoS Negl Trop Dis. 2019 Apr 26;13(4):e0007316. doi: 10.1371/journal.pntd.0007316. eCollection 2019 Apr.

12.

Elicitation of Broadly Protective Antibodies following Infection with Influenza Viruses Expressing H1N1 Computationally Optimized Broadly Reactive Hemagglutinin Antigens.

Sautto GA, Kirchenbaum GA, Ecker JW, Bebin-Blackwell AG, Pierce SR, Ross TM.

Immunohorizons. 2018 Aug 27;2(7):226-237. doi: 10.4049/immunohorizons.1800044.

PMID:
31022693
13.

A computationally designed H5 antigen shows immunological breadth of coverage and protects against drifting avian strains.

Ross TM, DiNapoli J, Giel-Moloney M, Bloom CE, Bertran K, Balzli C, Strugnell T, Sá E Silva M, Mebatsion T, Bublot M, Swayne DE, Kleanthous H.

Vaccine. 2019 Apr 17;37(17):2369-2376. doi: 10.1016/j.vaccine.2019.03.018. Epub 2019 Mar 21. Erratum in: Vaccine. 2019 Sep 3;37(37):5664.

PMID:
30905528
14.

A review of H5Nx avian influenza viruses.

Nuñez IA, Ross TM.

Ther Adv Vaccines Immunother. 2019 Feb 22;7:2515135518821625. doi: 10.1177/2515135518821625. eCollection 2019. Review.

15.

Universal Influenza Vaccine Approaches Using Full-Length or Head-Only Hemagglutinin Proteins.

Ross TM.

J Infect Dis. 2019 Apr 8;219(Supplement_1):S57-S61. doi: 10.1093/infdis/jiz004.

PMID:
30715379
16.

H2 influenza viruses: designing vaccines against future H2 pandemics.

Reneer ZB, Ross TM.

Biochem Soc Trans. 2019 Feb 28;47(1):251-264. doi: 10.1042/BST20180602. Epub 2019 Jan 15. Review.

PMID:
30647144
17.

Correction: Split inactivated COBRA vaccine elicits protective antibodies against H1N1 and H3N2 influenza viruses.

Allen JD, Ray S, Ross TM.

PLoS One. 2018 Dec 27;13(12):e0210043. doi: 10.1371/journal.pone.0210043. eCollection 2018.

18.

Elicitation of Protective Antibodies against 20 Years of Future H3N2 Cocirculating Influenza Virus Variants in Ferrets Preimmune to Historical H3N2 Influenza Viruses.

Allen JD, Jang H, DiNapoli J, Kleanthous H, Ross TM.

J Virol. 2019 Jan 17;93(3). pii: e00946-18. doi: 10.1128/JVI.00946-18. Print 2019 Feb 1.

19.

Dengue virus and the host innate immune response.

Uno N, Ross TM.

Emerg Microbes Infect. 2018 Oct 10;7(1):167. doi: 10.1038/s41426-018-0168-0. Review.

20.

Split inactivated COBRA vaccine elicits protective antibodies against H1N1 and H3N2 influenza viruses.

Allen JD, Ray S, Ross TM.

PLoS One. 2018 Sep 28;13(9):e0204284. doi: 10.1371/journal.pone.0204284. eCollection 2018. Erratum in: PLoS One. 2018 Dec 27;13(12):e0210043.

21.

Development of a Pan-H1 Influenza Vaccine.

Darricarrère N, Pougatcheva S, Duan X, Rudicell RS, Chou TH, DiNapoli J, Ross TM, Alefantis T, Vogel TU, Kleanthous H, Wei CJ, Nabel GJ.

J Virol. 2018 Oct 29;92(22). pii: e01349-18. doi: 10.1128/JVI.01349-18. Print 2018 Nov 15.

22.

Lymphoid tissue fibrosis is associated with impaired vaccine responses.

Kityo C, Makamdop KN, Rothenberger M, Chipman JG, Hoskuldsson T, Beilman GJ, Grzywacz B, Mugyenyi P, Ssali F, Akondy RS, Anderson J, Schmidt TE, Reimann T, Callisto SP, Schoephoerster J, Schuster J, Muloma P, Ssengendo P, Moysi E, Petrovas C, Lanciotti R, Zhang L, Arévalo MT, Rodriguez B, Ross TM, Trautmann L, Sekaly RP, Lederman MM, Koup RA, Ahmed R, Reilly C, Douek DC, Schacker TW.

J Clin Invest. 2018 Jul 2;128(7):2763-2773. doi: 10.1172/JCI97377. Epub 2018 May 21.

23.

H3N2 influenza viruses in humans: Viral mechanisms, evolution, and evaluation.

Allen JD, Ross TM.

Hum Vaccin Immunother. 2018;14(8):1840-1847. doi: 10.1080/21645515.2018.1462639. Epub 2018 May 14. Review.

24.

Anthropologia: An (Almost) Forgotten Early Modern History.

Ross TM.

J Hist Ideas. 2018;79(1):1-22. doi: 10.1353/jhi.2018.0000.

PMID:
29398656
25.

Towards a universal influenza vaccine: different approaches for one goal.

Sautto GA, Kirchenbaum GA, Ross TM.

Virol J. 2018 Jan 19;15(1):17. doi: 10.1186/s12985-017-0918-y. Review.

26.

The effect of frailty on HAI response to influenza vaccine among community-dwelling adults ≥ 50 years of age.

Moehling KK, Nowalk MP, Lin CJ, Bertolet M, Ross TM, Carter CE, Susick M, Saul SG, Kaynar AM, Bromberger JT, Zimmerman RK.

Hum Vaccin Immunother. 2018 Feb 1;14(2):361-367. doi: 10.1080/21645515.2017.1405883. Epub 2017 Dec 20.

27.

Impact of age and pre-existing influenza immune responses in humans receiving split inactivated influenza vaccine on the induction of the breadth of antibodies to influenza A strains.

Nuñez IA, Carlock MA, Allen JD, Owino SO, Moehling KK, Nowalk P, Susick M, Diagle K, Sweeney K, Mundle S, Vogel TU, Delagrave S, Ramgopal M, Zimmerman RK, Kleanthous H, Ross TM.

PLoS One. 2017 Nov 1;12(11):e0185666. doi: 10.1371/journal.pone.0185666. eCollection 2017.

28.

Infection of Ferrets with Influenza Virus Elicits a Light Chain-Biased Antibody Response against Hemagglutinin.

Kirchenbaum GA, Allen JD, Layman TS, Sautto GA, Ross TM.

J Immunol. 2017 Dec 1;199(11):3798-3807. doi: 10.4049/jimmunol.1701174. Epub 2017 Oct 27.

29.

Computationally Optimized Broadly Reactive Hemagglutinin Elicits Hemagglutination Inhibition Antibodies against a Panel of H3N2 Influenza Virus Cocirculating Variants.

Wong TM, Allen JD, Bebin-Blackwell AG, Carter DM, Alefantis T, DiNapoli J, Kleanthous H, Ross TM.

J Virol. 2017 Nov 30;91(24). pii: e01581-17. doi: 10.1128/JVI.01581-17. Print 2017 Dec 15.

30.

Elicitation of Protective Antibodies against a Broad Panel of H1N1 Viruses in Ferrets Preimmune to Historical H1N1 Influenza Viruses.

Carter DM, Darby CA, Johnson SK, Carlock MA, Kirchenbaum GA, Allen JD, Vogel TU, Delagrave S, DiNapoli J, Kleanthous H, Ross TM.

J Virol. 2017 Nov 30;91(24). pii: e01283-17. doi: 10.1128/JVI.01283-17. Print 2017 Dec 15.

31.

Discrete Dynamical Modeling of Influenza Virus Infection Suggests Age-Dependent Differences in Immunity.

Keef E, Zhang LA, Swigon D, Urbano A, Ermentrout GB, Matuszewski M, Toapanta FR, Ross TM, Parker RS, Clermont G.

J Virol. 2017 Nov 14;91(23). pii: e00395-17. doi: 10.1128/JVI.00395-17. Print 2017 Dec 1.

32.

Broadened immunity and protective responses with emulsion-adjuvanted H5 COBRA-VLP vaccines.

Allen JD, Owino SO, Carter DM, Crevar CJ, Reese VA, Fox CB, Coler RN, Reed SG, Baldwin SL, Ross TM.

Vaccine. 2017 Sep 12;35(38):5209-5216. doi: 10.1016/j.vaccine.2017.07.107. Epub 2017 Aug 5.

PMID:
28789850
33.

Solvent modified spin crossover in an iron(iii) complex: phase changes and an exceptionally wide hysteresis.

Phonsri W, Harding P, Liu L, Telfer SG, Murray KS, Moubaraki B, Ross TM, Jameson GNL, Harding DJ.

Chem Sci. 2017 May 1;8(5):3949-3959. doi: 10.1039/c6sc05317c. Epub 2017 Mar 23.

34.

C3d regulates immune checkpoint blockade and enhances antitumor immunity.

Platt JL, Silva I, Balin SJ, Lefferts AR, Farkash E, Ross TM, Carroll MC, Cascalho M.

JCI Insight. 2017 May 4;2(9). pii: 90201. doi: 10.1172/jci.insight.90201. eCollection 2017 May 4.

35.

Generation of Monoclonal Antibodies against Immunoglobulin Proteins of the Domestic Ferret (Mustela putorius furo).

Kirchenbaum GA, Ross TM.

J Immunol Res. 2017;2017:5874572. doi: 10.1155/2017/5874572. Epub 2017 Feb 14.

36.

Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination.

Lee J, Boutz DR, Chromikova V, Joyce MG, Vollmers C, Leung K, Horton AP, DeKosky BJ, Lee CH, Lavinder JJ, Murrin EM, Chrysostomou C, Hoi KH, Tsybovsky Y, Thomas PV, Druz A, Zhang B, Zhang Y, Wang L, Kong WP, Park D, Popova LI, Dekker CL, Davis MM, Carter CE, Ross TM, Ellington AD, Wilson PC, Marcotte EM, Mascola JR, Ippolito GC, Krammer F, Quake SR, Kwong PD, Georgiou G.

Nat Med. 2016 Dec;22(12):1456-1464. doi: 10.1038/nm.4224. Epub 2016 Nov 7.

37.

Commentary on 'Dissecting the hemagglutinin head and stalk specific IgG antibody response in healthcare workers following pandemic H1N1 vaccination'.

Ross TM.

NPJ Vaccines. 2016 Jul 28;1:16004. doi: 10.1038/npjvaccines.2016.4. eCollection 2016. No abstract available.

38.

Expression and Purification of Virus-like Particles for Vaccination.

Arevalo MT, Wong TM, Ross TM.

J Vis Exp. 2016 Jun 2;(112). doi: 10.3791/54041.

39.
40.

Development of a Zika vaccine.

Tripp RA, Ross TM.

Expert Rev Vaccines. 2016 Sep;15(9):1083-5. doi: 10.1080/14760584.2016.1192474. Epub 2016 Jun 6. Review. No abstract available.

PMID:
27212079
41.

Design and Characterization of a Computationally Optimized Broadly Reactive Hemagglutinin Vaccine for H1N1 Influenza Viruses.

Carter DM, Darby CA, Lefoley BC, Crevar CJ, Alefantis T, Oomen R, Anderson SF, Strugnell T, Cortés-Garcia G, Vogel TU, Parrington M, Kleanthous H, Ross TM.

J Virol. 2016 Apr 14;90(9):4720-4734. doi: 10.1128/JVI.03152-15. Print 2016 May.

42.

Are plasma mineral levels related to antibody response to influenza vaccination in older adults?

Kaynar AM, Nowalk MP, Lin CJ, Moehling KK, Susick M, Bakalov V, Pitt BR, Bain DJ, Ross TM, Saul SG, Raymund M, Zimmerman RK.

Hum Vaccin Immunother. 2016 Apr 2;12(4):1003-8. doi: 10.1080/21645515.2015.1113358. Epub 2016 Jan 11.

43.

Use of computational and recombinant technologies for developing novel influenza vaccines.

Wong TM, Ross TM.

Expert Rev Vaccines. 2016;15(1):41-51. doi: 10.1586/14760584.2016.1113877. Epub 2015 Nov 23. Review.

PMID:
26595182
44.

Sequential Infection in Ferrets with Antigenically Distinct Seasonal H1N1 Influenza Viruses Boosts Hemagglutinin Stalk-Specific Antibodies.

Kirchenbaum GA, Carter DM, Ross TM.

J Virol. 2015 Nov 11;90(2):1116-28. doi: 10.1128/JVI.02372-15. Print 2016 Jan 15.

45.

Portrait of Dr. Ted M. Ross.

Ross TM.

Hum Vaccin Immunother. 2016 Mar 3;12(3):560-2. doi: 10.1080/21645515.2015.1116286. No abstract available.

46.

Emerging Infections of CNS: Avian Influenza A Virus, Rift Valley Fever Virus and Human Parechovirus.

Wiley CA, Bhardwaj N, Ross TM, Bissel SJ.

Brain Pathol. 2015 Sep;25(5):634-50. doi: 10.1111/bpa.12281. Review.

47.

Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as Adjuvant.

Beljanski V, Chiang C, Kirchenbaum GA, Olagnier D, Bloom CE, Wong T, Haddad EK, Trautmann L, Ross TM, Hiscott J.

J Virol. 2015 Oct;89(20):10612-24. doi: 10.1128/JVI.01526-15. Epub 2015 Aug 12.

48.

Identification of Hemagglutinin Residues Responsible for H3N2 Antigenic Drift during the 2014-2015 Influenza Season.

Chambers BS, Parkhouse K, Ross TM, Alby K, Hensley SE.

Cell Rep. 2015 Jul 7;12(1):1-6. doi: 10.1016/j.celrep.2015.06.005. Epub 2015 Jun 25.

49.

The inflammatory response to influenza A virus (H1N1): An experimental and mathematical study.

Price I, Mochan-Keef ED, Swigon D, Ermentrout GB, Lukens S, Toapanta FR, Ross TM, Clermont G.

J Theor Biol. 2015 Jun 7;374:83-93. doi: 10.1016/j.jtbi.2015.03.017. Epub 2015 Apr 3.

50.

Cocktail of H5N1 COBRA HA vaccines elicit protective antibodies against H5N1 viruses from multiple clades.

Crevar CJ, Carter DM, Lee KY, Ross TM.

Hum Vaccin Immunother. 2015;11(3):572-83. doi: 10.1080/21645515.2015.1012013.

Supplemental Content

Support Center